Three Weeks Left to Comment on New Dementia Measures

Article

You have until December 15 to view and comment on the new set of evidence-based quality measure for dementia.

The American Academy of Neurology is encouraging neurologists, and the public, to offer comments on a new set of evidence-based quality measure for dementia. With a commitment to developing new measures for neurologic conditions to enhance quality of care and patient safety, the AAN wants as many people as possible to know that the comment period is open until December 15, 2010.

End-of-life issues related to dementia care, staging of dementia, and counseling related to safety issues and driving risks are among the issues addressed in the measurement, developed by a work group that included AAN member Germaine Odenheimer, MD, FAAN, who served as the Dementia Measure Development Work Group Co-Chair along Jerry C. Johnson, MD from the American Geriatrics Society.

Implementation of the dementia measures can be done in quality improvement programs and/or pay-for-reporting programs, such as the Physician Quality Reporting Initiative. The measures can also be used for meeting requirements set by the American Board of Medical Specialties for Maintenance of Certification requirements for Performance in Practice (PIP) Modules. The AAN describes PIP as a “a two-part quality improvement program designed for ‘clinically active’ physicians to evaluate whether they have shown practice improvement over the 10-year” maintenance of certification cycle.”

The Consortium for Performance Improvement (CPI), part of the American Medical Association, is also soliciting comments for the measurement set, stating that all comments are welcome and will be compiled and shared with the work group for consideration. Comments can be submitted via a CPI survey after viewing the measures on the CPI site.

Related Videos
Bhanu Prakash Kolla, MBBS, MD: Treating Sleep with Psychiatric Illness
Awaiting FDA Decision on MDMA Assisted Therapy, with Bessel van der Kolk, MD
Bessel van der Kolk, MD: The Future of MDMA Assisted Therapy in PTSD
Bessel van der Kolk, MD: What MDMA-Assisted Therapy Taught us About PTSD
Why Are Adult ADHD Cases Climbing?
How to Adequately Screen for and Treat Cognitive Decline in Primary Care
Depression Screening: Challenges and Solutions at the Primary Care Level
James R. Kilgore, DMSc, PhD, PA-C: Cognitive Decline Diagnostics
HCPLive Five at APA 2024 | Image Credit: HCPLive
John M. Oldham, MD: A History of Personality Disorder Pathology
© 2024 MJH Life Sciences

All rights reserved.